EPIX Achieves Discovery Milestone in Collaboration with GlaxoSmithKline
News Aug 16, 2007
Using its proprietary, integrated computational-medicinal chemistry approach to drug discovery, EPIX has identified three lead candidates that will move forward into lead optimization in this first collaborative G-protein coupled receptor (GPCR) discovery program.
Under the collaboration, EPIX is entitled to receive a $3 million milestone payment from GSK in the next 30 days.
“We are extremely pleased with the progress of our collaboration with GSK,” stated Michael G. Kauffman, M.D., Ph.D., chief executive officer of EPIX.
“In addition to our joint focus on developing PRX-03140, our proprietary 5-HT4 agonist, for the treatment of Alzheimer’s disease, EPIX and GSK have agreed upon the three discovery program targets and are making significant progress on each program. We are on-schedule and expect to continue moving forward to achieve key milestones across all of our collaborative programs,” Kauffman added.
In December 2006, EPIX and GSK announced a worldwide multi-target strategic collaboration to discover, develop and market medicines targeting four G-protein coupled receptors (GPCRs) for the treatment of a variety of diseases, including EPIX’s novel 5-HT4 partial agonist program, PRX-03140, which is in early-stage clinical development for the treatment of Alzheimer's disease.
As part of the collaboration, EPIX received total initial payments of $35 million, including $17.5 million through the purchase of its common stock at a premium, and may be eligible to earn up to $1.2 billion in milestones across the four GPCR programs.
Under the collaboration, EPIX is also entitled to receive tiered double-digit royalties of sales by GSK on all collaboration-developed product sales. The alliance is conducted through GSK’s Center of Excellence for External Drug Discovery (CEEDD).
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Compound as Effective as FDA-Approved Drugs Against Life-Threatening InfectionsNews
Purdue University researchers have identified a new compound that in preliminary testing has shown itself to be as effective as antibiotics approved by the Food and Drug Administration to treat life-threatening infections while also appearing to be less susceptible to bacterial resistance.READ MORE